Cancer Summaries and Commentaries™: Report from Orlando on Advances in the Treatment of GvHD

Release Date: December 24, 2019
Expiration Date: December 24, 2020
Media: Internet - based

Activity Overview

Cancer Summaries and Commentaries™: Report From Orlando on Advances in the Treatment of GVHD is an online activity developed to update healthcare providers on data presented at the 2019 American Society of Hematology Annual Meeting, held in December in Orlando, Florida. This activity reviews 9 abstracts with some of the most interesting and clinically relevant data on graft-versus-host disease (GVHD) presented at the meeting. Short summaries of key clinical data for selected abstracts is accompanied by commentary from experts in the field and provide insight regarding the importance of the studies and the possible impact of their findings on clinical practice.

Benefits of Participating

This activity will better prepare you to:

• Learn about new strategies targeting the biology of graft-versus-host disease (GVHD)
• Hear about novel biomarker algorithms to predict survival in patients with GVHD
• Learn about current and new treatment strategies for GVHD
• Explore emerging targets to the prevention of GVHD
• Be informed about recent clinical trials data and earn CME credit

Acknowledgement of Commercial Support

This activity is supported by educational grants from Incyte Corporation and Mallinckrodt LLC.

Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with hematologic malignancies. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with hematologic malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Outline graft-versus-host disease (GVHD) biology, pathogenesis, and risk factors to better manage GVHD
• Explain findings from recently conducted trials that assessed emerging strategies for the treatment and management of GVHD
• Consider recent clinical trial data in the context of evolving treatment paradigms in the management of patients with GVHD

Faculty, Staff, and Planners’ Disclosures

Faculty

James L.M Ferrara, MD, DSc
Ward-Coleman Chair in Cancer Medicine
Professor and Director, Hematologic Malignancies Translational Research Center
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Other support: IP- Patent for biomarkers of acute GvHD

Shernan Holtan, MD
Assistant Professor of Medicine
Medical Director for the Clinical Trials Office for Cell, Gene, and Immunotherapy University of Minnesota
Minneapolis, MN

Disclosures: Other support: IP- Patent for biomarkers of acute GvHD

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.